抗血管内皮生长因子治疗后1型与2型近视性脉络膜新生血管特征及疗效比较
该回顾性研究纳入171例接受抗血管内皮生长因子治疗并随访至少1年的活动性近视性脉络膜新生血管患者,比较1型与2型CNV的基线特征及治疗结局。1型CNV(占19.3%)基线最佳矫正视力更差且黄斑变性更重,但两型治疗后视力均显著改善约2.2行,复发率和注射次数无差异。基线最佳矫正视力、近视性黄斑变性严重程度及视网膜下高反射渗出是最终最佳矫正视力的显著预测因素,而CNV类型不是独立预测因素。
要点
- 1型近视性CNV占19.3%,基线最佳矫正视力更差且黄斑变性较2型更重。
- 两型CNV抗VEGF治疗后视力均改善约2.2行,复发率和注射次数无差异。
- 基线最佳矫正视力、黄斑变性严重程度和视网膜下高反射渗出可预测最终视力。
核心结论
- 尽管1型CNV的黄斑变性更严重,但两型近视性CNV均从抗VEGF治疗中显著获益。
- 这些发现支持将治疗扩展至1型CNV,并强调需要个体化管理策略。
研究设计与样本
- 回顾性研究,纳入171例接受抗血管内皮生长因子治疗并随访至少1年的活动性近视性CNV患者。
- 使用光学相干断层扫描对CNV进行分型。
- 比较基线特征(包括最佳矫正视力、近视性黄斑病变分级和OCT表现)及治疗结局。
主要发现
- 1型CNV占19.3%,其基线最佳矫正视力较2型更差,黄斑变性较2型更晚期。
- 两型CNV治疗后视力均显著改善约2.2行,复发率和注射次数无差异。
- 多变量分析显示,基线最佳矫正视力、近视性黄斑变性严重程度和视网膜下高反射渗出是最终最佳矫正视力的显著预测因素,而CNV类型不是独立预测因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aims to compare baseline characteristics and treatment outcomes of Type 1 and Type 2 myopic choroidal neovascularization (CNV) after 1 year of antivascular endothelial growth factors therapy and identify clinical factors associated with visual outcomes, recurrence rates, and injection numbers. METHODS: In this retrospective study, we reviewed 171 patients with active myopic CNV treated with antivascular endothelial growth factors therapy and followed for at least 1 year. CNV types were classified using optical coherence tomography. Baseline characteristics, including best-corrected visual acuity, myopic maculopathy grade, and optical coherence tomography findings, were compared. RESULTS: Type 1 CNVs (19.3% of cases) exhibited worse baseline best-corrected visual acuity and more advanced macular degeneration than Type 2 CNVs. Both types showed significant visual improvement equivalent to 2.2 lines post-therapy, with no difference in recurrence rates or injection numbers. Multivariate analysis revealed that baseline best-corrected visual acuity, severity of myopic macular degeneration, and presence of subretinal hyperreflective exudation were significant predictors of final best-corrected visual acuity, while CNV type was not an independent predictor. CONCLUSION: Despite more severe macular degeneration in Type 1 CNV, both types myopic CNVs benefit significantly from antivascular endothelial growth factors therapy. These findings support extending treatment to Type 1 CNVs and highlight the need for individualized management strategies.
引用
- Tew TB, Hsieh YT, Tsui MC, et al. COMPARISON OF CHARACTERISTICS AND TREATMENT OUTCOMES OF TYPE 1 AND TYPE 2 MYOPIC CHOROIDAL NEOVASCULARIZATION AFTER ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina. 2025. PMID: 40690698. doi:10.1097/IAE.0000000000004611
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。